Internal Medicine, Endocrinology, Diabetes, & Metabolism · Port Charlotte, FL
NPI
1487697272
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
3611 Tamiami Trl Ste B
Port Charlotte, FL, 33952
Phone (941) 235-0542
Groups this clinician bills Medicare through
Medicare paid, 2024
$296K
6,810 services
Medicare patients, 2024
1,056
Average age 74
Drug cost, 2024
$9.3M
10,707 prescriptions
Company payments, 2025
$224K
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Arelis M Madera was code 99214 (office e&m - established), 1,803 times for 849 patients. In total Arelis M Madera billed 6,810 services in 52 codes, and Medicare paid $296K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-02-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,803 | 849 | $91.04 | $164K |
| 95251 Test - Miscellaneous | Office | 1,636 | 602 | $25.35 | $41K |
| 36415 Venipuncture Blood Collection | Office | 394 | 302 | $8.65 | $3,408 |
| 83036 Blood Count | Office | 291 | 225 | $9.52 | $2,770 |
| 80053 Clinical Chemistry | Office | 257 | 218 | $10.35 | $2,660 |
| 82962 Clinical Chemistry | Office | 205 | 160 | $3.21 | $658 |
| 84443 Clinical Chemistry | Office | 203 | 169 | $16.46 | $3,341 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 197 | 41 | $4.93 | $971 |
| 84439 Clinical Chemistry | Office | 195 | 160 | $8.84 | $1,724 |
| 82570 Clinical Chemistry | Office | 181 | 170 | $5.08 | $919 |
| 82043 Clinical Chemistry | Office | 181 | 170 | $5.66 | $1,024 |
| 80061 Clinical Chemistry | Office | 180 | 161 | $13.12 | $2,362 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 177 | 160 | $12.48 | $2,209 |
| 99204 Office E&M - New | Office | 124 | 124 | $114.59 | $14K |
| 99205 Office E&M - New | Office | 105 | 105 | $155.86 | $16K |
By year: 2022 $273K for 5,567 services; 2023 $267K for 5,300 services; 2024 $296K for 6,810 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 394 | 302 | $8.65 | $3,408 |
| 83036 Blood Count | 291 | 225 | $9.52 | $2,770 |
| 80053 Clinical Chemistry | 257 | 218 | $10.35 | $2,660 |
| 82962 Clinical Chemistry | 205 | 160 | $3.21 | $658 |
| 84443 Clinical Chemistry | 203 | 169 | $16.46 | $3,341 |
| 84439 Clinical Chemistry | 195 | 160 | $8.84 | $1,724 |
| 82043 Clinical Chemistry | 181 | 170 | $5.66 | $1,024 |
| 82570 Clinical Chemistry | 181 | 170 | $5.08 | $919 |
| 80061 Clinical Chemistry | 180 | 161 | $13.12 | $2,362 |
| 82533 Clinical Chemistry | 27 | 23 | $15.97 | $431 |
Medicare prescription drug claims, 2024
In 2024, the drug Arelis M Madera prescribed most often to Medicare patients was Ozempic (Semaglutide), with 733 prescriptions and refills. In total Arelis M Madera wrote 10,707 Medicare prescriptions that cost $9.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 733 | 1,440 | 209 | $1.4M |
| Levothyroxine Sodium Generic | 671 | 1,972 | 237 | $5,950 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 415 | 1,086 | 225 | $61K |
| Mounjaro Tirzepatide | 385 | 718 | 128 | $773K |
| Tresiba Flextouch U-100 Insulin Degludec | 362 | 1,001 | 162 | $284K |
| Tresiba Flextouch U-200 Insulin Degludec | 354 | 915 | 125 | $462K |
| Rosuvastatin Calcium Generic | 350 | 1,034 | 122 | $4,482 |
| Kerendia Finerenone | 287 | 634 | 80 | $398K |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 280 | 662 | 77 | $557K |
| Novolog Flexpen Insulin Aspart | 278 | 729 | 140 | $66K |
| Trulicity Dulaglutide | 273 | 507 | 80 | $488K |
| Metformin Hcl Er Metformin Hcl | 267 | 789 | 106 | $1,835 |
| Ezetimibe Generic | 260 | 772 | 91 | $6,142 |
| Farxiga Dapagliflozin Propanediol | 251 | 640 | 76 | $354K |
| Jardiance Empagliflozin | 235 | 572 | 77 | $327K |
Brand drugs: 6,285 claims; generic drugs: 3,264 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Arelis M Madera $224K ($224K in general payments such as food, travel and fees) from 29 companies. The largest payer was Lilly USA, LLC with $101K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 149 | $101K |
| Novo Nordisk Inc NVO | 38 | $37K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 27 | $35K |
| Dexcom, Inc. DXCM | 24 | $29K |
| Abbott Laboratories ABT | 28 | $13K |
| Neurocrine BioSciences, Inc. NBIX | 13 | $3,894 |
| Sanofi-Aventis U.S. LLC SNY | 12 | $3,122 |
| Chiesi USA, Inc. | 1 | $325 |
| Ascendis Pharma Endocrinology Inc ASND | 9 | $318 |
| Radius Health, Inc. | 5 | $147 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.